Nanocellulose as an embedding matrix and applications thereof
A versatile drug delivery system comprised of plant-based nanocellulose can be used for providing high loading and extended release for virtually any drug. This system is made from nanocrystalline cellulose chemically cross-linked to form a hydrogel. This versatile hydrogel-based drug delivery system can be functionalized to support extended release of oral dosing, relieving patient burden and increasing quality of life.
1. A method of forming hydrogels containing a biologically active drug compound or therapeutic agent encapsulated therein for delivery to a patient,
the hydrogels formed from cellulose-based materials selected from the group consisting of sulfated crystalline nano cellulose (CNC) and TEMPO (2,2,6,6-tetramethylpiperidine-1-oxyl radical) cellulose nanofibers (CNF) comprising
i) forming cross-linked sulfated crystalline nanocellulose (CNC) using a basic solution and one or more chemical crosslinking agents, and
ii) forming hydrogels with TEMPO (2,2,6,6-tetramethylpiperidine-1-oxyl radical) cellulose nanofibers (CNF) using an aqueous solution containing ionic crosslinking agents,
said hydrogels formed by
iii) hydrating the nano cellulose (CNC) or TEMPO (2,2,6,6-tetramethyl-piperidine-1-oxyl radical) cellulose nanofibers (CNF) under high-powered sonication to form a clear solution followed by
iv) adding the chemical or ionic crosslinking agents to form a crosslinked hydrogel, comprising a fibrous network with an internal surface having pore sizes and permeability for encapsulation of the biologically active drug compound or therapeutic agent
wherein the biologically active drug compound encapsulated is insulin and wherein the therapeutic agent encapsulated is pyridostigmine bromide, the insulin exhibiting controlled release from the crosslinked hydrogel of at least 48.5% of the encapsulated insulin over a 150 hour period and the pyridostigmine bromide exhibiting controlled release of 100% from the crosslinked hydrogel in a 24 hour period,
said crosslinked hydrogels containing the insulin or pyridostigmine bromide formed by adding the insulin or pyridostigmine bromide to the crosslinked hydrogels.
2. The method of claim 1 , wherein the ionic crosslinking agents cause metal-coordinated crosslinking of the TEMPO-oxidized cellulose.
3. The method of claim 1 , wherein the hydrogel further includes one or more compounds that increase small molecule encapsulation.
4. The method of claim 3 , wherein the one or more compounds comprises β-cyclodextrin.
5. The method of claim 2 , wherein the ionic crosslinking agent is selected from a group consisting of aluminum nitrate, calcium chloride, sodium chloride, and hydrochloric acid.
6. The method of claim 1 , wherein the pore size and permeability of the hydrogel is controlled by varying the mixing speed, mixing method, pH, and/or temperature or a combination thereof used during formation of the hydrogels.
7. The method of claim 1 , wherein the pore size and permeability of the crosslinked hydrogel is controlled by selection of the one or more crosslinking agents.
8. The method of claim 1 , wherein the crosslinked hydrogel produced is stable in humid environments and temperatures from −25° C. to 100° C.
9. The method of claim 1 , wherein the insulin and pyridostigmine bromide and exhibit sustained release for an extended period of time.